AI
CYTK icon

Analytic Investors’s Cytokinetics CYTK Stock Holding History

Analytic Investors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-74,206
Closed -$523K – 618
2016
Q1 		$523K Sell
74,206
-9,631
-11% -$70.4K 0.01% 481
2015
Q4 		$877K Buy
+83,837
New +$822K 0.01% 417

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Analytic Investors's CYTK Position: Q2 2016 in Review

Analytic Investors sold out of Cytokinetics (CYTK) in Q2 2016, closing a stake of 74,206 shares — an estimated $523K sold.

Analytic Investors first reported a position in CYTK in Q4 2015 and held it in 2 quarters. The position peaked at $877K in Q4 2015. 95 funds tracked by Wall St. Rank hold CYTK as of Q2 2016.

  • Analytic Investors reported no remaining Cytokinetics position as of Q2 2016 after selling out during the quarter.
  • Analytic Investors sold 74,206 Cytokinetics shares in Q2 2016, an estimated $523K.
  • Analytic Investors first reported a position in Cytokinetics in Q4 2015 and held it in 2 quarters.
  • Analytic Investors's Cytokinetics position peaked at $877K in Q4 2015.
  • 95 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2016.

Based on Analytic Investors's 13F filing for Q2 2016, filed 11 Aug 2016.